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 Clostridium perfringens type C produces beta toxin, which is a primary virulence 
determinate that can cause necrotic enteritis in neonatal animals.  Vaccines directed 
against C. perfringens toxins have shown to be efficacious in preventing disease.  
However, the production of a commercial vaccine requires not only an efficacious 
antigen, but also testing methods for quantifying antigens and potency on final product.  
This research was undertaken to fulfill a need for the reduction in small animal usage to 
produce and deliver vaccines.  The current testing methods are performed in vivo 
according to the Code of Federal Regulations number 9 (9CFR) United States 
Department of Agriculture (USDA) and European Pharmacopeia (EP) monograph 
guidelines.  With limited in vitro alternatives, the aim of this work was to develop an 
enzyme-linked immunosorbent assay (ELISA) to be able to measure C. perfringens type 
C beta toxoid, independent of laboratory animals.  To accomplish this, investigational 
polyclonal and monoclonal antibody candidates were screened for their specificity to beta 
toxin and toxoid through western blot and ELISA.  Additionally, through a neutralization 
assay, the capability to neutralize beta toxin was demonstrated.  Through this process, 
one polyclonal antibody and one monoclonal antibody were selected and an in-process 
 
 
 
 
ELISA for quantifying beta toxoid was developed.  By using the ELISA to quantify beta 
toxoid, the current practice of testing in animals could be reduced.   
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CHAPTER I 
 
INTRODUCTION  
 Clostridium perfringens, a Gram positive anaerobic rod shaped bacterium, is a 
major cause of enteric disease in both humans and livestock.  One such enteric disease is 
necrotic enteritis, a severe disease found in animals that can have a significant negative 
financial impact to agricultural markets (Keyburn et al., 2010; Smedley et al., 2004).  In 
addition to animal diseases, C. perfringens causes food poisoning and gas gangrene in 
humans.  There are five toxinotypes, A thru E, of C. perfringens that are classified based 
on the type of toxins each produces.  C. perfringens type C produces alpha and beta 
toxin, with beta toxin being the primary virulence factor of necrotic enteritis in neonates.     
 C. perfringens can be found in many environments, such as soil, waste water, 
food, feces and in both healthy human and animal intestines as normal flora.  Vaccination 
of animals can help prevent outbreaks of disease in livestock.  These vaccines use 
inactivated whole bacteria, recombinant proteins and/or purified toxoids.  One obstacle to 
producing more efficacious vaccines is complying with required potency testing as 
mandated by the United States Department of Agriculture (USDA) and European 
Pharmacopoeia (EP).  Currently, the in vivo methods available for potency testing cause 
pain, suffering and death in laboratory animals.  Development of an in vitro assay to 
measure vaccine potency would minimize animal use and support commercialization of 
effective vaccines.  This is long overdue as C. perfringens species have been known since 
the turn of the century and scientists have been searching for effective vaccines since the 
early 1900s.       
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1.1 HISTORY OF CLOSTRIDIUM PERFRINGENS 
 In 1892, William Welch and George Nuttall discovered Bacillus aerogenes 
capsulatus during the postmortem examination of a 38 year old man at John Hopkins 
University.  The use of cultivation media and dyes (i.e., methylene-blue, gentian-violet 
and fuchsine) permitted Welch and Nuttall to observe the bacterium’s morphological 
features by fixing and staining the bacteria for microscopy.  They observed that Bacillus 
aerogenes capsulatus was a rod shaped bacilli that was at times encapsulated (Welch and 
Nuttall, 1892).  In addition, Welch and Nuttall observed the bacilli grew anaerobically as 
small colonies were present in the bottom two-thirds (oxygen depleted region) of an agar 
tube, while the upper third (microaerobic) had no growth.  Based on these observations, 
they arrived at the name Bacillus aerogenes capsulatus (Welch and Nuttall, 1892).  Over 
time the bacterium became known as Bacillus welchii and Clostridium welchii, before 
being renamed as Clostridium perfringens (Dembek, 2008).   
 
1.2 MORPHOLOGY AND CLASSIFICATION OF CLOSTRIDIUM   
 Clostridium is a genus in the class Clostridia and the phylum Firmicutes.  This 
genus consists of more than 100 species; however, the four species most commonly 
associated with human and animal disease are C. perfringens, C. tetani, C. botulinum and 
C. difficile.  Clostridium spp. are non-motile, Gram positive rods that grow anaerobically 
and form spores (Uzal et al., 2016; Vasanthakumari, 2007).  A single bacterium of C. 
perfringens averages 0.6-2 µm in diameter by 1.3-6 µm in length and can be found in 
pairs, single rods and small clusters (Uzal et al., 2016; Vasanthakumari, 2007).  After 24 
hours of growth under anaerobic conditions, C. perfringens colonies are smooth, circular, 
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semi-translucent and approximately 2-5 mm in diameter (Uzal et al., 2016).  Bacteria 
categorized as anaerobes are incapable of growing in the presence of oxygen and can be 
further classified as either strict anaerobes or aerotolerant anaerobes.  Strict anaerobes, do 
not live when exposed to oxygen, while aerotolerant anaerobes grow anaerobically but 
can survive being exposed to oxygen (Uzal et al., 2016).  C. perfringens has the ability to 
survive under-micro-aerobic conditions, thus being classified as an aerotolerant anaerobe.     
 C. perfringens produces four major toxins that are essential for virulence.  In 
addition to being essential for virulence, the four major toxins of C. perfringens are used 
to classify the bacteria into five toxinotypes A, B, C, D and E (Table 1).  The four toxins 
being: alpha (CPA), beta (CPB), epsilon (ETX) and iota (ITX) (Uzal et al., 2014).  CPA 
causes damage to many cell types, including erythrocytes, hepatocytes and myocytes.  
CPA disrupts the cell surface phospholipid bilayers by cleavage of the phosphorylcholine 
head groups, which disrupts the cell membrane causing necrosis and cell lysis (Li et al., 
2013).  In livestock, cellular pore formation is a result of CPB toxin oligomerization on 
the cell surface via lipid rafts.  This causes an efflux of potassium ions and an influx of 
sodium and chloride ions causing an increase in turgor pressure leading to cell lysis 
(Geny and Popoff, 2006).  ETX is also a pore forming toxin that affects brain, lung and 
smooth muscle cells.  A remarkable feature of ETX is the ability to selectively cause 
death of oligodendrocytes without killing astrocytes, microglia or neurons of the central 
nervous system (Linden et al., 2015).  ITX is an A-B toxin consisting of the enzymatic 
protein Ia and the cell surface binding protein Ib.  Individually, the two components are 
inactive but together cause enterotoxemia by increasing intestinal cell permeability and 
cell rounding and death through ADP-ribosylation of G-actin (Sakurai et al., 2009).  
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These toxins contribute to the diversity of species and tissues affected by C. perfringens 
strains.   
 
Table 1: C. perfringens toxinotype classification based on the presence or absence of the  
four major toxin classes. 
Type Alpha (α) Beta (β) Epsilon (ε) Iota (ι) 
A + - - - 
B + + + - 
C + + - - 
D + - + - 
E + - - + 
 
1.3 INFECTIONS CAUSED BY C. PERFRINGENS 
 Each C. perfringens toxinotype is associated with specific human and/or animal 
diseases highlighting the versatility of this bacterium (Smedley et al., 2004; Uzal et al., 
2014).  C. perfringens type A and type C are the two toxinotypes associated with both 
human and animal disease.  In humans, type A strains can induce food poisoning, non-
foodborne gastrointestinal disease and gas gangrene mainly due to the effect of CPA.  
Type C strain infections in humans cause necrotic enteritis also known as pigbel.  This is 
an intestinal infection causing abdominal pain, vomiting and in severe cases death due to 
CPB toxemia (Uzal et al., 2014; Uzal and McClane, 2011).  In addition to human 
infections, all C. perfringens toxinotypes can infect adult animals; however, these 
infections are predominantly seen in neonates that have not established normal gut flora.  
C. perfringens type A causes gas gangrene infections in cattle, sheep, goats and horses 
that are similar to human infections.  When type C infections occur in livestock species, 
they cause necrotic enteritis and enterotoxemia (Uzal and McClane, 2011; Uzal et al., 
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2010).  Necrotic enteritis is one of the most important diseases of C. perfringens type C, 
which is found in goats, cattle, pigs and horses.   
 The CPB toxin produced by C. perfringens type C can cause a neurological 
disease that includes rigid paralysis, also known as opisthotonos, where the animals 
demonstrate backward arching of the head, neck and spine (Nagahama et al., 2015; 
Tweten, 2001).  This neurological involvement is due to the toxin being able to move into 
circulation and cross the blood brain barrier.  In adult sheep, the condition known as 
struck refers to a type C disease.  The presentation of struck within sheep is described as 
if they have been struck by lightning.    
 Characteristics of necrotic enteritis are hemorrhagic mucosal ulceration or 
superficial mucosal necrosis of the small intestine, which is often followed by death or 
acute neurological signs (Smedley et al., 2004).  The other toxinotypes, such as type B 
which produces CPA, CPB and ETX causes hemorrhagic dysentery in sheep.  
Enterotoxemia of sheep, goats and cattle and enteritis in dogs, cattle and  pigs are caused 
by type D (ETX) and type E (ITX) respectively (Uzal et al., 2014).  Each of the 
Clostridial toxinotypes has a specific pathogenesis; however, since this thesis focuses on 
the development of a CPB analytical assay, only C. perfringens type C will be further 
discussed.        
 
1.4 PATHOGENESIS OF C. PERFRINGENS TYPE C 
 Clostridium perfringens is found in soils, feces and human and animal digestive 
tracts.  For infections to occur in neonates, C. perfringens must first gain entry into the 
host digestive tract.  The normal intestinal microbiota takes time to develop a stable 
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community in newborns, which makes them highly susceptible to colonization by type C 
strains, resulting in disease in young animals (i.e., exposure 24 – 48 hours after birth) 
(Uzal et al., 2014; Uzal and McClane, 2011).  Transmission occurs via the fecal oral 
route by suckling contaminated teats, ingesting colostrum during nursing from mothers 
who carry the bacterium, licking contaminated objects in the surroundings, or by coming 
into close contact with contaminated fecal material from infected animals (Niilo, 1988).  
Susceptibility is believed to be due to low or absent proteinase activity in the neonate, 
and the trypsin inhibitors in colostrum may contribute to this problem (Uzal et al., 2016).  
Once the development of normal flora is established in young animals, opportunistic 
infections by toxinotype C bacteria are greatly reduced (Tweten, 2001).  While type C 
strain infections primarily occur in infant animals, adult animals are also susceptible to 
infections.  This is likely due to gastrointestinal factors that affect an increase in the pH 
of the stomach, which favors growth, colonization and toxin production in the intestine.  
A diet high in foods with trypsin inhibitors such as soybeans may contribute to the 
susceptibility of adult animals (Uzal et al., 2016).  Another factor contributing to type C 
strain infections are unvaccinated herds, where the mortality rate can be greater than 50% 
(Uzal and McClane, 2011).      
 Once C. perfringens toxinotype C bacteria reach the intestine, they adhere to the 
epithelium of the small intestine and secrete alpha and beta toxins causing necrosis.  The 
damage caused by CPB allows other toxins (i.e., CPA) to be introduced into the host’s 
blood (Nagahama et al., 2015).  Circulating CPA exacerbates the destruction of epithelial 
cells and permits invasion of bacteria.  All of this causes a cascade effect, which leads to 
increased toxin production, cellular necrosis, hemorrhage and death (Nagahama et al., 
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2015; Niilo, 1988).  These observations contribute to the belief that CPB is the most 
important toxin for virulence (Gurtner et al., 2010; Sayeed et al., 2008; Uzal et al., 2009; 
Vidal et al., 2008).     
 
1.5 EVIDENCE FOR THE INVOLVEMENT OF BETA TOXIN  
 A number of animal models have been used to determine the function of CPB as a 
virulence factor.  When animals and humans were given crude beta toxoid, they were 
protected against strain type C infections suggesting that CPB was an essential virulence 
factor (Walker et al., 1979).  A mouse model using intravenous injection of CPB from 
type C culture supernatants also demonstrated that CPB was important for virulence 
(Fisher et al., 2006).  Lethality of CPB is inhibited by monoclonal antibodies to CPB, 
protecting mice from a lethal intravenous challenge; however, lethality was not 
attenuated in mice with a monoclonal antibody to CPA (Fisher et al., 2006; Uzal and 
McClane, 2011).  In addition, studies using cpb null mutants to infect mice, rabbit and 
goats in an intestinal loop model demonstrated that cpb mutants are attenuated in 
virulence relative to the wild-type strains (Sayeed et al., 2008).  Taken together, CPB is 
essential for virulence in toxinotype C infections.   
 
1.6 CHARACTERIZATION OF BETA TOXIN 
 Bacterial toxins are generally classified as either endotoxins or exotoxins.  
Endotoxins are associated with the cell envelope of Gram negative bacteria which have a 
lipopolysaccharide complex associated with the outer membrane.  Exotoxins are proteins 
that are secreted by many Gram positive and Gram negative bacteria.  A subclass of 
8 
 
 
 
exotoxin is enterotoxins, which target the intestine and are commonly pore-forming 
toxins that disrupt cell membranes.  The CPB exists as a monomer or oligomer and is 
defined as an exotoxin that forms pores (Popoff, 2014; Shatursky et al., 2000).  The 
monomer is the toxic form and can readily convert to the nontoxic oligomer form in vitro 
(Sakurai and Nagahama, 2006); however, the oligomeric form is unable to dissociate 
back into the monomeric form.  The 35 kDa CPB is secreted during the post-exponential 
growth phase and is known to be susceptible to proteolytic and heat inactivation, but not 
by low pH (Sakurai and Duncan, 1978; Uzal and McClane, 2011; Vidal et al., 2008).  
The cpb gene is carried on a virulence plasmid found in type C isolates and codes for a 
336 amino acid protein containing a 27 amino acid leader sequence that is cleaved to 
form the mature beta toxin protein (Hunter et al., 1993; Nagahama et al., 2015; Sakurai et 
al., 2004; Uzal et al., 2010).  In susceptible cell lines, such as primary porcine cells, 
human umbilical vein endothelial cells (HUVEC), and human leukemia cells (HL-60 
cells),  CPB intoxication results in swelling and cell lysis (Nagahama et al., 2015; Uzal 
and McClane, 2011). 
 
1.7 MODE OF ACTION OF BETA TOXIN 
 The C. perfringens type C beta toxin is a pore forming toxin that forms 
multimeric complexes in HUVEC cell membranes (Steinthorsdottir et al., 2000) and 
cation-selective pores in phospholipid bilayers (Shatursky et al., 2000).  In addition, CPB 
induces swelling and cell lysis in the human leukemia cell line HL-60 (Nagahama et al., 
2003).  One hypothesis is that CPB monomers (35 kDa) are incorporated into susceptible 
membranes and oligomerize into ~228 kDa hexamers or heptamers to form a 
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transmembrane pore (Smedley et al., 2004).  More recently, it was postulated that CPB 
monomers recognized an unidentified receptor on the cell surface, then oligomerize to 
form a prepore and the prepore is inserted into the lipid bilayer to form a pore (Geny and 
Popoff, 2006; Popoff, 2014).  Irrespective of the mechanism, CPB induced cell death is 
initiated by the formation of pores that cause an efflux of K+ and Ca2+ with a concomitant 
influx of Na+ and Cl- ions resulting in cell lysis (Autheman et al., 2013; Nagahama et al., 
2003; Uzal et al., 2014).  To prevent infections in animals caused by the pore-forming 
CPB, prophylactic vaccination has mostly proven to be efficacious in preventing type C 
disease.      
 
1.8 VACCINES 
 Commercially available C. perfringens type C vaccines for veterinary use contain 
chemically inactivated cultures where the toxin is now referred to as toxoid of type C 
strains, or in combination with types A, B or D strains.  These inactivated cultures 
produce an antigenic response to the type C CPB despite detoxification of the antigen.  
The use of pure or mixed cultures concomitant with the production of extraneous proteins 
has created a situation where the efficacy of vaccines is highly variable, and has 
increased the demand for more reproducible and quantifiable antigens such as 
recombinant proteins. 
 The variability of vaccine preparations can be seen in a field trial for Per-C-
porc®.  In this trial, sows were given Per-C-porc® a type C toxoid vaccine, at a breeding 
facility that had experienced significant losses of piglets due to the C. perfringens type C 
disease.  Prior to vaccination, three batches of the Per-C-porc® vaccines were tested in 
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accordance with the European Pharmacopoeia, the same requirements as the Code of 
Federal Regulations number 9 (9CFR) USDA, in which there has to be at least 10 
international units (IU) of beta antitoxin per mL of rabbit serum (Springer and Selbitz, 
1999).  The results from the in vivo efficacy testing of the vaccine batches revealed that 
all three batches fulfilled the regulatory requirements, however the mean titer values 
varied greatly with a range of 17.14 to 98.23 IU beta antitoxin per mL in rabbit serum 
(Springer and Selbitz, 1999).  The titer fluctuation was due to inconstancies in antigen 
production, which resulted in different yields of toxin during fermentation that affected 
performance in efficacy testing.  The type C vaccine with the lowest IU beta antitoxin per 
mL rabbit serum result was used to vaccinate the sows.  During this study, there was a 
slight decrease in piglet loss when the sows were vaccinated and their piglets were 
administered benzylpenicillin potassium within the first three days of birth.  The need for 
antibiotic use shows the type C toxoid vaccines are not fully protective and antibiotics are 
needed to protect piglets from C. perfringens type C disease (Springer and Selbitz, 1999).  
The variability in manufacturing and the need for antibiotics highlighted the need for 
more efficacious vaccine strategies (Springer and Selbitz, 1999). 
Other vaccine approaches include the use of recombinant proteins expressed in 
Escherichia coli and harvested from solubilized inclusion bodies are used as immunogens 
to vaccinate animals (Zeng et al., 2011).  The vaccines had either monovalent 
recombinant α-toxin (CPA), a fusion protein of β2/β1 (CPB2B1), a trivalent fusion 
protein consisting of α/β2/β1-toxins (CPAB2B1) or a cocktail CPA plus CPB2B1.  These 
recombinant protein vaccines were administered to mice, cows and sows.  In a mouse 
toxin challenge model, mice were challenged at either 14 days or at 42 days post-
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vaccination.  Vaccine groups with CPA plus CPB2B1 or the multivalent CPAB2B1 had 
greater survival rates, even at day 42, than mice vaccinated with the monovalent CPA; 
suggesting that recombinant toxoids are viable vaccine candidates with extended efficacy 
(Zeng et al., 2011).  Histopathological examination of the mice intestines revealed that 
vaccinated mice, no matter the treatment, did not have gross pathological changes in 
contrast to the control mice.  In addition to pathology, antibody titers of serum from 
immunized mice, sows and cows and the colostrum from immunized sows and cows were 
also examined.  The highest neutralizing antibody titers were generated in mice but the 
sera and colostrum of sows and cows also had detectable titers.  Neutralizing antibodies 
in the colostrum implies the recombinant toxoids are able to stimulate maternal 
antibodies for protection of their offspring (Zeng et al., 2011).  Immunization with 
CPB2B1 or CPA plus CPB2B1 produced greater neutralizing antibody titers than did the 
CPA monovalent vaccine.  In addition, fusion proteins increase the level of safety and 
effectiveness relative to the use of whole-cell bacterial vaccines, as the numerous 
extraneous proteins are eliminated (Zeng et al., 2011).   
In addition to the toxin cocktail mentioned above, a recombinant C. perfringens 
type C beta toxoid (rBT) produced in E. coli and purified from inclusion bodies was 
evaluated as a vaccine candidate (Milach et al., 2012).  Potency testing of this vaccine 
was performed according to the 9CFR USDA and EP and was shown to be non-toxic 
through evaluation of the lethal dose (LD50) for the recombinant compared to the native 
beta toxin.  This group showed that 100 µg of rBT inoculated intravenously did not 
exhibit any clinical signs of toxicity, as compared to 0.4 µg per kg LD50 for the wild-type 
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beta toxin.  In addition, the rBT was able to induce rabbit serum with 14 IU beta antitoxin 
per mL, which is superior to a vaccine using the wild-type toxins.      
Vaccines using recombinant proteins/toxoids are considered to be more stable, 
safer and efficacious, and have the potential to be new candidates for commercial 
vaccines (Salvarani et al., 2013).  This is illustrated by a study where pregnant sows were 
vaccinated twice with a bivalent vaccine consisting of C. perfringens alpha (rTA) and 
beta (rTB) recombinant toxoids (Salvarani et al., 2013).  Protective antibody titers of anti-
alpha toxin (~6.0 IU per mL) and anti-beta toxin (~14.5 IU per mL) were produced.  
Importantly, the antibody titers to alpha and beta toxins were higher than the USDA 
required minimums (Salvarani et al., 2013).  The litters from vaccinated sows also 
exhibited titers of neutralizing antibodies to alpha and beta toxins by passive 
immunization through colostrum.  The litters had an alpha antitoxin titer of ~4.2 IU per 
mL and a beta antitoxin titer of ~10.9 IU per mL, which also met the USDA required 
minimum standard (Salvarani et al., 2013).  These data demonstrate the vaccine and 
immunization strategy elicited a maternal immune response comparable to other vaccine 
formulations (Matisheck and McGinley, 1986; Salvarani et al., 2013).  Overall, using 
recombinant toxoids may be less labor intensive and safer to produce, and can potentially 
reduce the costs of manufacturing the vaccines. 
Immunogenic, non-toxin proteins were identified using serum from C. 
perfringens infected birds.  These two non-toxin, highly immunogenic proteins were 
pyruvate: ferredoxin oxidoreducate (PFO) and elongation factor-Tu (EF-Tu) (Jang et al., 
2012).  PFO is an enzyme that catalyzes the conversion of pyruvate into acetyl-CoA, 
while EF-Tu facilitates binding of charged tRNAs to the A-site of ribosomes.  These 
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proteins were cloned, over-expressed in E. coli, and used in infection protection studies.  
The efficacies of these proteins were compared to two different recombinant toxins by 
assessing the levels of protection achieved in a C. perfringens disease infection model.  
The cloned toxins used in the challenge were the C. perfringens alpha toxin and NetB, a 
necrotic enteritis B-like toxin.  All four proteins were mixed individually with a 
commercial oil-in-water adjuvant (Jang et al., 2012) and tested for their ability to protect 
chickens against infections with virulent cultures of Eimeria maxima and C. perfringens.  
In this model, the first vaccination occurred in chicks one day of age and the second 
vaccination occurred when the birds were seven days old.  At 14 days of age, the birds 
received a live culture of E. maxima by oral lavage (Jang et al., 2012).  Four days after 
administering the E. maxima culture, the birds were orally given live C. perfringens 
cultures and 20 days post-hatch the serum antibodies were measured.  Increased antibody 
titers and weight gain were observed in birds vaccinated with NetB and PFO.  
Additionally, the NetB and PFO recombinant protein vaccines were more efficacious 
against the double challenge of E. maxima and C. perfringens challenge than was the 
alpha toxin and EF-Tu recombinant protein vaccines (Jang et al., 2012).  However, alpha 
toxin and EF-Tu vaccinates were efficacious in comparison to the controls.  This data 
highlights a different approach in selecting non-toxin vaccine candidates.    
 While much of the current research for development for C. perfringens type C 
vaccines seems to be progressing toward the use of recombinants, these will not replace 
current commercial vaccines in the near future; hence, in vitro assays to detect vaccine 
components are necessary to facilitate production and regulatory compliance.   
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1.9 CURRENT ASSAYS – IN VIVO AND IN VITRO 
 Prevention of C. perfringens type C infections relies heavily on vaccination with 
inactivated whole bacteria.  For vaccines to be efficacious, they should be able to elicit a 
protective immune response in the host animal.  The commercially available C. 
perfringens type C vaccines produce neutralizing antibodies against the clostridial toxins.  
Production needs and regulatory requirements necessitate in-process testing for antigen 
production.  Currently, C. perfringens type C toxin materials are assayed using an in vivo 
test method, known as the L+ test.  In this assay, the toxin product is diluted and 
combined with a known amount of anti-toxin antibody, which is specific to the beta 
toxin.  The different dilutions are intravenously administered to five mice for each 
dilution and the dilution which is lethal to 80% of the mice determines the potency 
concentration.  The concentration at the specific dilution is further used to calculate the 
amount of non-toxin antigen to formulate into final vaccine.    
 The current required test for final vaccine potency involves the use of mice and 
rabbits and is mandated in the 9CFR USDA guidelines and EP monograph (United States 
Department of Agriculture, 2017a) .  According to the USDA guidelines, the in vivo test 
requires a minimum of eight rabbits subcutaneously administered with one half of the 
largest recommended dose, or less, based on the target host species.  A second injection is 
given 20-23 days following the first administration.  All surviving rabbits after 14-17 
days post vaccination are bled, the serum pooled and the serum tested for antitoxin levels.  
As described in the 9CFR 113.111 (United States Department of Agriculture, 2017a), the 
antitoxin neutralizing antibody level is determined through a dilution series using an 
antitoxin standard.  The neutralizing antibody levels are assessed against C. perfringens 
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beta toxin and are estimated in vivo using a mouse neutralization test (Ebert et al., 1999).  
To meet the prescribed standard, vaccines must have at least 10 IU of standard beta 
antitoxin per milliliter of rabbit serum.  The use of animals in these validated assays has 
led to a desire to develop new assays that reduce the number of animals required.  
 The development of in vitro assays would be cost effective by greatly reducing 
the number of animals used each year.  Efforts to reduce the number of animals required 
for toxin validation have led to eliminating the use of mice; however, rabbits are still 
required for sera generation (Ebert et al., 1999).  While it is desirable to use only in vitro 
assays, these assays must be comparable to in vivo tests and to date only proof-of-
principle studies have been performed, and these assays must be validated and accepted 
by the USDA and EP (Redhead et al., 2011).  In summary, producing the toxoid is labor 
intensive and potency testing is time consuming and requires the use of animals.  While 
work is being done to develop new vaccines against CPB, improvements in the potency 
testing are needed.   
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CHAPTER II 
 
ABSTRACT  
 Clostridium perfringens is a Gram positive anaerobic rod and a major cause of 
enteric disease in both humans and livestock.  There are five C. perfringens toxinotypes, 
(i.e., A, B, C, D and E) that are classified based on the type of toxins each produces.  The 
focus of this work is on the beta toxin produced by C. perfringens type C.  The primary 
virulence determinant of C. perfringens type C is the beta toxin, which causes necrotic 
enteritis in neonatal animals.  Fortunately, cattle and pig vaccines directed against C. 
perfringens toxins are efficacious.  Production of a commercial vaccine requires not only 
an efficacious antigen, but also testing methods for quantifying antigens and potency 
determination of the finished vaccine.  These methods are performed in vivo according to 
the Code of Federal Regulations number 9 (9CFR) United States Department of 
Agriculture (USDA) and European Pharmacopeia (EP) monograph guidelines.  
Currently, there are limited in vitro alternatives to assessing C. perfringens type C beta 
toxin in fermentation media or final vaccine potency.  With the generation of polyclonal 
and monoclonal antibody reagents, an in vitro method could be developed to measure C. 
perfringens type C toxoid material independent of laboratory animals implementing the 
principles of the 3Rs (replacement, reduction and refinement).      
 
2.1 INTRODUCTION 
 This work focuses on filling the need for an in vitro method to measure the C. 
perfringens type C toxoid, which will help reduce the use of laboratory animals and 
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facilitate vaccine production.  An enzyme-linked immunosorbent assay (ELISA) was 
developed to quantitate the C. perfringens type C beta toxoid from cultivation media.  
This could improve accuracy in formulating vaccines in contrast to the in vivo method of 
estimating the amount of toxin.  The necessary reagents were developed and the assay 
format assessed as shown in the following section.  In addition, results from the 
developed ELISA are presented.      
 
2.2 MATERIALS AND METHODS 
2.2.1 BACTERIAL CULTIVATION CONDITIONS   
 C. perfringens type C was grown in a 10 liter Celligen BLU single use fermenter 
containing media components of soy peptone, casein hydrolysate (Tryptone), yeast 
extract, antifoam and dextrose.  Actively growing culture was aseptically added at 20 
mL/L to the fermenter and incubated at 36°C ± 2°C for approximately 3-6 hours with pH 
maintained between 7.0 – 7.5.   
 
2.2.2 TOXIN AND TOXOID PREPARATION 
 For toxin preparation, the fermentation culture was centrifuged at 15,000g using a 
Sorvall RC 6+ centrifuge for 30 minutes at 4°C; supernatants were pooled and cell pellets 
discarded. The supernatant was passed through a Sterile MidiCap Sartopore 2 filtration 
unit containing a 0.45 + 0.2 μm membrane.   
 For toxoid preparation, the fermentation culture was chemically inactivated with 
formaldehyde prior to centrifugation at 15,000g using a Sorvall RC 6+ centrifuge for 30 
minutes at 4°C; supernatants were pooled and cell pellets discarded. The supernatant was 
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passed through a Sterile MidiCap Sartopore 2 filtration unit containing a 0.45 + 0.2 μm 
membrane.    
 A control of C. perfringens type A toxoid culture medium was provided by the 
bacterial processing group at Zoetis Inc., Lincoln, NE. 
 
2.2.3 ISOLATION OF MONOCLONAL ANTIBODIES    
 All in vivo work was conducted after ethical review and in compliance with local, 
national and international guidance.  Specific pathogen-free BALB/c mice (17 to 20 g; 3 
mice; no gender was specified) were immunized according to the Maine Biotechnology 
Services, Inc. (MBS) Rapid Immunization Multiple Sites (RIMMS) protocol.  Mice were 
immunized five times within the 20 day period at multiple sites; each injection time point 
used 0.5mL of C. perfringens type C toxoid adjuvanted vaccine.  At day 20, blood was 
collected and serum screened by ELISA to determine the specific antibody titer.  Based 
on the screening results, the mice received an additional boost following the test bleed 
and a second test bleed was taken 10 days after the last boost. Based on the test bleed 
screen, MBS then selected one mouse for fusion that had the highest anti-CPB titer.  The 
spleen was dissected from the mouse and the splenocytes were fused with SP2/0 
myeloma cells to create hybridomas.  The fused cells were cultured and supernatants 
were evaluated for antibody production.  Hybridoma supernatants were assessed for CPB 
toxoid specificity by an indirect ELISA.  There were 41 type C toxoid specific clones that 
were selected.  These hybridoma positive culture supernatants were further processed 
through three rounds of subcloning by limiting dilution.   
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 A mouse hybridoma secreting a beta toxin specific monoclonal antibody was 
obtained from the Center for Veterinary Biologics (CVB) Ames, IA courtesy of Dr. Paul 
Hauer.  This monoclonal antibody detected the 38 kDa protein band associated with CPB 
toxoid on western blot.  The CVB monoclonal antibody was subsequently used as a 
positive control on confirmatory assays such as western blot, ELISA and neutralization 
assay.  
  
2.2.4 POLYCLONAL ANTIBODIES    
 Goat anti-C. perfringens Type C toxoid polyclonal antibodies were provided by 
from the Laboratory Sciences group at Zoetis Inc., Kalamazoo, MI.  All in vivo work was 
conducted after ethical review and in compliance with local, national, and international 
guidance.   
 
2.2.5 INDIRECT ELISA  
 Indirect ELISA was used to screen hybridoma supernatants for antibodies from 
MBS.  To determine if the hybridoma supernatants had antibodies to C. perfringens type 
C toxoid only, a positive indirect ELISA was used with a type C antigen coating and a 
negative indirect ELISA performed with C. perfringens type A antigen coated on the 
assay plates.  C. perfringens type C toxoid antigen was diluted in 0.01 M borate buffer 
(sodium tetraborate in purified water, pH 9.0 – 9.2) for a final concentration of 300 µg 
antigen per 100 µL buffer.  Polystyrene flat bottom 96-well plates (Nunc MaxiSorp) were 
incubated overnight at 4°C with a volume of 100 µL per well of diluted antigen.  The 
next day, plates were washed three times with 0.1 M phosphate buffered saline 
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containing 0.05% tween 20 (PBST).  The plates were blocked by adding 200 µL/well of 
1% casein sodium in PBST and then incubated at 37°C ± 2°C for 1 hour.  After blocking, 
the plates were washed three times with PBST followed by 50 µL of each hybridoma 
supernatant dispensed into their respective well on the plate.  The plates were covered 
and incubated for 60 minutes at 37°C ± 2°C.  Post incubation, plates were washed three 
times with PBST followed by the addition of 50 µL/well of diluted peroxidase conjugated 
goat anti-mouse IgG heavy and light chain (Jackson ImmunoResearch).  The peroxidase 
conjugate was diluted in 1% casein sodium in PBST at 1:3,000 dilution and then 
incubated for 60 minutes at 37°C ± 2°C.  Following incubation, the plates were washed 
three times and 50 µL/well of ABTS (2, 2'-Azino-di-3-ethylbenzthiazoline-6-sulfonate) 
peroxidase substrate (Kirkgaard & Perry Laboratories) was added and the plates were 
incubated at room temperature for 15 to 20 minutes.  The reaction of the conjugated 
enzyme with the ABTS substrate produces a greenish color.  The optical density (OD) of 
each well is determined using values of 405 nm minus 490 nm as determined on a Vmax 
kinetic microplate reader (Molecular Devices) and the SoftMax Pro software 6.3.  The 
same conditions and reagent concentrations were used to determine if the hybridoma 
supernatants had antibody present to C. perfringens type A toxoid for the negative 
indirect ELISA screen.  Hybridomas were selected using the criteria of the well in the 
positive assay having an absorbance of ≥ 0.08 and the corresponding well in the negative 
assay having an absorbance of ≤ 0.05.  
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2.2.6 SDS-PAGE AND WESTERN BLOTTING      
 Proteins present in the C. perfringens type C beta toxin preparation were 
visualized on a 4-12% Bis-Tris SDS-PAGE gel using a GelCode Blue Safe Protein 
coomassie blue stain (Pierce Biotechnology).  For western blot analysis, proteins from the 
gel were transferred to a nitrocellulose membrane using the iBlot™ 2 gel transfer device 
and iBlot™ 2 Transfer Stacks containing the nitrocellulose membranes (Invitrogen).  
Non-specific binding was blocked using 0.5% gelatin (from cold water fish skin) in 
PBST.  This was followed by incubation at room temperature with anti-CPB antibodies.  
The blots were washed with 0.05% tween 20 in PBS and then incubated for 30 minutes at 
room temperature with peroxidase conjugated goat anti-mouse IgG H+L (Jackson 
ImmunoResearch).  Membranes were developed with TMB (3, 3’, 5, 5’–
Tetramethylbenzidine) peroxidase substrate 3-component system (Kirkgaard & Perry 
Laboratories). 
    
2.2.7 NEUTRALIZATION ASSAY 
 The neutralization assay was used to assess the ability of antibodies to neutralize 
the C. perfringens type C beta toxin.  Vero cells, derived from the kidney of normal adult 
African green monkey, were cultivated in Eagles Modified Essential Medium (EMEM) 
(Gibco, Calsbad, CA) supplemented with 5% fetal bovine serum (FBS) (Atlanta 
Biologicals, Lawrenceville, GA) and maintained in a 37˚C humidified chamber with 5% 
CO2.  Vero cells were seeded in 96-well plates and grown to a confluent monolayer with 
a cell density of 125,000 cells per well.  The antibody samples were diluted either 1:2 or 
1:4 in EMEM medium.  Two-fold serial dilutions were made across the dilution plate, 
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leaving the last two columns for positive and negative control wells (100 µL/well).  
Clostridium perfringens type C beta toxin was added to the dilution plate containing the 
diluted antibody samples (100 µL/well).  The dilution plate was incubated for 2 hours at 
37°C ± 2°C with 5% CO2.  After incubation, 200 µL of antibody/toxin material from the 
dilution plate was transferred to the actively growing Vero cell plate.  Vero plates were 
then incubated for 2 days at 37°C ± 2°C with 5% CO2.  Following incubation, cells were 
assessed under a microscope for cytopathic effect (CPE).  Wells having intact cells in a 
confluent monolayer indicate the antibody neutralized the beta toxin challenge.  Wells 
lacking a monolayer indicate the antibody was unable to neutralize the beta toxin, 
resulting in CPE on the cells.   
     
2.2.8 CHECKERBOARD ASSAY 
 A checkerboard assay method was used to determine the optimal dilutions of the 
capture (polyclonal) and indicator (monoclonal) antibodies for the in-process assay to 
measure C. perfringens type C toxoid.  A checkerboard pattern was obtained by using a 
polystyrene flat bottom 96-well plate with the capture antibody dilutions down the y-axis 
(row A through row H) and the indicator antibody dilutions were along the x-axis 
(column 1 through column 12).  Each plate was coated with capture antibody diluted in 
0.01 M borate buffer; with the starting dilution of the capture antibody on the plate in row 
A being 1:250 and followed by two-fold serial dilution from row A through H and the 
plates were then incubated overnight at 4°C.  Plates were washed the next day three times 
with PBST and then blocked with 1% casein sodium in PBST (200 µL/well) and 
incubated at 37°C ± 2°C for 1 hour.  After blocking and washing the plates, C. 
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perfringens type C antigen was added to each of the wells at a constant concentration, 
300 µg antigen per 200 µL per well diluted in 1% casein sodium in PBST.  The plates 
were covered and incubated for 1 hour at 37°C ± 2°C.  Post incubation period, the plates 
were washed three times with PBST and the indicator antibody diluted in 1% casein 
sodium was added to each plate.  The starting dilution of the indicator antibody on the 
plate in column 1 was 1:250 and followed by two-fold serial dilution from columns 1 
through 12.  The plates were covered and incubated for 1 hour at 37°C ± 2°C.  Post 
incubation, plates were washed three times with PBST, followed by the addition of 100 
µL/well of a 1:2,000 dilution of the conjugate antibody (i.e., peroxidase conjugated goat 
anti-mouse) diluted in 1% casein sodium in PBST and then incubated for 1 hour at 37°C 
± 2°C.  Following incubation, the plates were washed three times and ABTS peroxidase 
substrate was added (50 µL/well), and the plates were incubated at room temperature for 
15 to 20 minutes.  The plates were read at 405 minus 490 nm with Vmax kinetic 
microplate reader (Molecular Devices) and the SoftMax Pro software 6.3.  The average 
OD were plotted for both capture and indicator antibodies to determine the optimal 
dilutions.                              
 
2.2.9 SANDWICH ELISA 
 A sandwich ELISA method was used to develop the in-process assay for 
measuring C. perfringens type C toxoid.   Goat anti-C. perfringens type C toxoid 
polyclonal antibody was diluted in 0.01 M borate buffer and dispensed onto polystyrene 
flat bottom 96-well plates (Nunc MaxiSorp) that were incubated overnight at 4°C with 
diluted antibody (100 µL/well).  The next day, plates were washed three times with 0.1 M 
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PBST and blocked with 1% casein sodium in PBST (200 µL/well) and incubated at 37°C 
± 2°C for 1 hour.  After blocking, plates were washed three times with PBST followed by 
the addition of C. perfringens type C toxoid samples.  The plates were covered and 
incubated for 1 hour at 37°C ± 2°C.  Post-incubation, plates were washed three times 
with PBST, followed by the addition of anti-C. perfringens type C monoclonal antibody 
diluted in 1% casein sodium in PBST (100 µL/well).  The plates were covered and 
incubated for 1 hour at 37°C ± 2°C.  Post-incubation, plates were washed three times 
with PBST, followed by the addition of 100 µL/well of diluted peroxidase conjugated 
goat anti-mouse IgG H+L (Jackson ImmunoResearch).  The conjugate was diluted in 1% 
casein sodium in PBST at 1:2,000 dilution and then incubated for 1 hour at 37°C ± 2°C.  
Following incubation, the plates were washed three times and 50 µL/well of ABTS 
peroxidase substrate (Kirkgaard & Perry Laboratories) was added, and the plates 
incubated at room temperature for 15 to 20 minutes.  The OD values at 405 nm minus 
490 nm were determined using a Vmax kinetic microplate reader (Molecular Devices) 
and the SoftMax Pro software 6.3. 
 
2.2.10 IN-PROCESS ELISA 
 The following describes the developed in-process ELISA method for measuring 
C. perfringens type C toxoid.  The polyclonal capture antibody, anti-C. perfringens beta 
goat 31, was diluted in 0.01 M borate buffer and dispensed onto polystyrene flat bottom 
96-well plates (Nunc MaxiSorp) that were incubated overnight at 4°C with diluted 
antibody (100 µL/well).  The next day, plates were washed three times with 0.1 M PBST 
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and blocked with 1% casein sodium in PBST (200 µL/well) and incubated at 37°C ± 2°C 
for 1 hour.  
 During the blocking step, the reference, positive control and test samples are 
vortexed for 15 seconds (3 by 5 seconds) at maximum vortex speed.  Then dilutions of 
reference, positive control and test articles are prepared by making a 1:54 dilution in 1% 
casein sodium in PBST.  In a dilution plate, 150 µL of 1% casein sodium in PBST is 
dispensed into each well column 2 – 11 and rows C – G (Fig.1).  In row B, 300 µL of 
1:54 diluted reference, positive control and each test article is added to wells as labeled 
and shown in Figure 1.  Two-fold dilutions are preformed down the plate by mixing the 
samples in row B and transferring 150 µL to row C.  Changing pipette tips between rows 
and repeated through row G.            
  
 
Fig. 1: In-process assay 96-well plate configuration.  Ref (Reference), + (Positive 
Control), T01-03 are test samples. 
 
 The blocked plates were washed three times with PBST and 100 µL from the 
dilution plates was transferred to blocked plates as follows; beginning in row G through 
row B, material is transferred to the respective wells.  The outer wells on the plate (Fig. 
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1) receive 100 µL of PBST.  The plates are covered and incubated at 37°C ± 2°C for 1 
hour.  Post incubation, plates were washed three times with PBST, followed by the 
addition of indicator antibody, mouse anti-C. perfringens type C toxoid monoclonal 
antibody (mAb 23) diluted 1:2,000 in 1% casein sodium in PBST (100 µL/well).  The 
plates were covered and incubated at 37°C ± 2°C for 1 hour and after incubation the 
plates were washed three times with PBST.  The peroxidase conjugate antibody, goat 
anti-mouse, was diluted at 1:2,000 in 1% casein sodium in PBST and added at 100 µL 
per well.  The plates were covered and incubated at 37°C ± 2°C for 1 hour and after 
incubation the plates were washed three times with PBST.  After the final washing step, 
50 µL/well of ABTS peroxidase substrate was added to all wells on the plates.  The plates 
were read at 405 nm minus 490 nm with Vmax kinetic microplate reader (Molecular 
Devices) and the SoftMax Pro software 6.3. with five second shake pre-read targeting a ≥ 
0.8 OD for the first dilution of the reference (average of wells B2 and B7 as shown in 
Figure 1).   
 
2.3 RESULTS 
2.3.1 CHARACTERIZATION OF POLYCLONAL ANTIBODIES 
 Two polyclonal antibodies were provided by Zoetis Inc.; specifically, anti-C. 
perfringens beta goat 11 and anti-C. perfringens beta goat 31.  The two polyclonal 
antibodies were characterized by western blot analysis to confirm recognition of the 38 
kDa beta protein.  Both goat 11 and 31 polyclonals recognized the 38 kDa protein band 
of C. perfringens type C (Fig. 2).  As expected, polyclonal antibodies bound to a band at 
38 kDa that corresponds to the CVB beta toxin positive control included on the western 
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blot.  To assess the ability of the polyclonal antibodies to neutralize beta toxin, their 
neutralizing activity was evaluated (Table 2).  Anti-C. perfringens beta goat 31 had slight 
neutralizing activity, while anti-C. perfringens beta goat 11 lacked neutralizing activity.  
Overall, neither of the polyclonal antibodies had pronounced neutralizing capabilities; 
however, the antibodies only need to capture the beta toxoid through epitope binding and 
neutralizing capability is not required.  To assess their potential utility in an ELISA, the 
polyclonal antibodies were evaluated using an indirect ELISA (Fig. 3).  The assay 
distinguished the differences between the antibodies where anti-C. perfringens beta goat 
31 bound the C. perfringens type C toxoid material but anti-C. perfringens beta goat 11 
did not.  For this reason, the goat 31 anti- C. perfringens beta toxoid antibody was 
selected as the polyclonal antibody to be used as the capture for developing an in-process 
assay to measure type C material.      
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Fig. 2: Western blot analysis depicting C. perfringens type C beta toxin specific protein 
binding by polyclonal antibodies 31 and 11.  Lane 1 molecular weight marker.  Lane 2 
negative goat serum control, 1:4,000 dilution.  Lane 3 positive control monoclonal to beta 
from the Center for Veterinary Biologics (CVB), 1:80,000 dilution. Lane 4 through 6 are 
anti-C. perfringens beta goat 31 at 1:10,000, 1:20,000 and 1:40,000 dilutions respectfully.  
Lane 7 through 9 are anti-C. perfringens beta goat 11 at 1:10,000, 1:20,000 and 1:40,000 
dilutions respectfully.  Lane 10 peroxidase conjugate control for lane 3, goat anti-mouse 
at 1:4,000 dilution.  Lane 11 peroxidase conjugate control for lane 4 – 9, donkey anti-goat 
at 1:4,000 dilution. 
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Table 2: Polyclonal antibody 31 weakly neutralizes CPB.  
Sample Average End Point Dilution (CPE)a 
Anti-C. perfringens beta 
goat 11 <2 
Anti-C. perfringens beta 
goat 31 8 
Positive Control              
(Beta toxin Anti-sera) 256 
Negative Control         
(Alpha toxin Anti-sera) <2 
aAverage values of two replicates. 
 
 
 
 
Fig. 3: Polyclonal antibody 31 produced a greater signal relative to polyclonal antibody 
11 when evaluated by indirect ELISA.  Data is representative of the mean OD (OD405 - 
OD490) for each dilution completed in duplicate.  The individual polyclonal antibodies 
were at an initial concentration of 1:4,000 and diluted 2-fold across the plate. 
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2.3.2 MONOCLONAL ANTIBODY SELECTION 
 Experiments were carried out to determine the most appropriate monoclonal 
antibody for use in the ELISA format as the indicator antibody.  Forty-one hybridoma 
monoclonal antibodies met the selection criteria of having an OD greater than or equal to 
0.08 on C. perfringens type C toxoid plates with less than or equal to 0.05 OD on C. 
perfringens type A toxoid plates when assessed by MBS.  Fulfilling these criteria 
demonstrate there was minimal cross reactivity of the 41 monoclonal antibodies for CPA.   
 The supernatants of hybridoma monoclonal antibodies were further characterized 
by western blot analysis to confirm recognition of the 38 kDa beta protein.  Of the 41 
monoclonal antibodies screened, 11 recognized a 38 kDa protein band (Fig. 4).  These 11 
monoclonal antibodies were also evaluated using a sandwich ELISA (Fig. 5).  Of the 11 
monoclonal antibodies, two demonstrated strong reactivity throughout the dilution series.  
Importantly, monoclonal antibody 23 gave a strong signal even at the highest dilution, 
suggesting a high affinity for the antigen.  An ideal monoclonal antibody for an assay has 
high affinity for the antigen and neutralizing activity.  The neutralizing activity suggests 
the antibody recognizes and binds to epitopes on the antigen necessary for protection.  To 
assess the neutralizing capability of the 11 monoclonal antibodies, neutralizing activity 
was evaluated (Table 3).  Of the 11 hybridoma monoclonal antibodies, five had 
neutralizing activity, including monoclonal antibody 23.   
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Fig. 4: Western blot analysis depicting C. perfringens type C beta toxin specific protein 
binding by different supernatants of hybridoma monoclonal antibodies.  Lane 1 molecular 
weight marker.  Eight of the 11 individual monoclonal antibodies to detect beta toxin in 
lanes 2 through 9 (11, 13, 22, 23, 33, 35, 37, and 40) at a 1:4 dilution.  Lane 10 positive 
control monoclonal to beta from the CVB at 1:10,000 dilution.  Lane 11 peroxidase 
conjugate control, goat anti-mouse at 1:4,000 dilution.   
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Fig. 5: Hybridoma monoclonal antibodies 23 and 37 produced the greatest signal relative 
to the other investigational antibodies when evaluated by sandwich ELISA.  Data is 
representative of the mean OD (OD405 - OD490) for each dilution completed in duplicate.  
The individual monoclonal antibodies were at an initial concentration of 1:2 and diluted 
2-fold across the plate. 
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Table 3: Capability of hybridoma monoclonal candidates to neutralize CPB.      
Monoclonal Number Average End Point Dilution (CPE)a 
1 <2 
11 <2 
13 32 
18 <2 
22 <2 
23 128 
33 64 
35 64 
37 128 
40 <2 
41 <2 
CVB 10A2 <2 
Fusion Media Control <2 
Positive Control               
(Beta toxin Anti-sera) 256 
Negative Control         
 (Alpha toxin Anti-sera) <2 
aAverage values of two replicates. 
 
 
 The five hybridoma candidates which showed to neutralize the beta toxin were 
selected and expanded, purified, concentrated and were then reevaluated by western blot 
to confirm detection of the 38 kDa protein band (Fig. 6), neutralizing activity (Table 4), 
and absence of cross reactivity of alpha toxin by indirect ELISA (Fig. 7).  Since alpha 
toxin is present in C. perfringens type C cultures, a false positive result could be obtained 
if the antibody also reacted to the alpha toxin.  To assess the cross reactivity of the five 
monoclonal antibodies with neutralizing activity to beta toxin, they were analyzed using 
positive and negative indirect ELISA (Fig. 7).  The five monoclonal antibodies 
demonstrated specificity for C. perfringens type C beta toxoid and did not cross react 
with type A toxoid.  Taken together, these data demonstrate that monoclonal antibody 23 
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has specificity to the beta toxin by western blot, a high affinity as shown by ELISA, 
strong neutralizing activity, and no cross reactivity with C. perfringens type A.  For these 
reasons, monoclonal antibody 23 was chosen for use as the indicator antibody in 
developing an in-process ELISA to measure C. perfringens type C toxoid. 
 
 
Fig. 6: Western blot analysis depicting C. perfringens type C beta toxin specific protein 
binding by monoclonal antibody candidates.  Lane 1 molecular weight marker.  Lane 2 
positive control monoclonal to beta from the CVB at 1:20,000 dilution.  Lane 3 through 7 
monoclonal antibodies 13, 23, 33, 35 and 37 at a 1:10,000 dilution.  Lane 8 peroxidase 
conjugate control, goat anti-mouse at 1:4,000 dilution.   
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Table 4: Monoclonal candidates to neutralize CPB.      
Monoclonal Number Average End Point Dilution (CPE)a 
13 512 
23 4096 
33 1024 
35 2048 
37 4096 
CVB 10A2 <4 
Positive Control              
(Beta toxin Anti-sera) 256 
Negative Control         
(Alpha toxin Anti-sera) <4 
aAverage values of two replicates. 
 
 
Fig. 7: Monoclonal antibodies 23 and 37 produced the greatest signal relative to positive 
control, 10A2, when evaluated by indirect ELISA to C. perfringens type C.  All 
investigational antibodies were negative when evaluated by indirect ELISA to C. 
perfringens type A.  Data is representative of mean OD (OD405 - OD490) for each dilution 
completed in duplicate.  The individual monoclonal antibodies were diluted 2-fold across 
the plate with a 1:500 starting dilution. 
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2.3.3 IN-PROCESS ELISA DEVELOPMENT AND OPTIMIZATION STEPS 
 The following are two flow charts outlining the steps used during the 
development and optimization of an in-process ELISA.  
Development Steps: 
 
Optimization Steps: 
 
Determining capture and indicator anitbody 
use dilutions 
Establish reference material 
Establish positive control material 
Outline of developed in-process ELISA 
method for optimization 
Define assay variables 
Determine intra-assay repeatability  
Assess within-plate precision or variability 
between sample positions on a single plate 
Intermediate precision to assess results 
obtained between technicians 
Assess actual and theoretical values to show 
accuracy of the assay 
Robustness for assay flexibility 
Establishing a positive control range for the 
assay 
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2.3.4 IN-PROCESS ELISA DEVELOPMENT STEPS 
2.3.4.1 CAPTURE AND INDICATOR ANTIBODY USE DILUTION 
 The appropriate antibody dilutions for use in the in-process ELISA need to be 
determined initially to optimize the signal to background ratio.  This is important so the 
background does not interfere with the signal from the antigen being measured.  The 
dilutions of the capture antibody (i.e., goat anti-C. perfringens type C 31) and indicator 
antibody (i.e., mouse anti-C. perfringens type C clone 23) were determined by 
performing a checkerboard assay for evaluating optimal dilutions.  Capture antibody 
dilutions down the y-axis of a 96-well plate (row A through row H) and the indicator 
antibody dilutions were along the x-axis (column 1 through column 12). The plates were 
read and the average OD’s were plotted for both capture and indicator antibodies to 
determine optimal use dilutions.  The optimal use dilution for the capture antibody was 
determined to be 1:500, while the indicator antibody optimal use dilution was determined 
to be 1:2,000 (Fig. 8 and 9).                
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Fig. 8: Optimal dilution for polyclonal antibody 31 was determined to be 1:500 by 
checkerboard assay.  Black dashed line highlights the 1:500 dilution.  The capture 
starting dilution was 1:250 in row A and diluted two fold to 1:32,000 in row H. 
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Fig. 9: Optimal dilution for monoclonal antibody 23 was determined to be 1: 2,000 by 
checkerboard assay.  Black dashed line highlights the 1:2,000 dilution.  The indicator 
starting dilution was 1:250 in column 1 and diluted two fold to 1:512,000 in column 12. 
 
2.3.4.2 FULL CURVE ANALYSIS OF REFERENCE 
 Reference material must be representative of the samples that will be analyzed in 
the ELISA.  Since in-process samples are cultures of C. perfringens type C, a 
representative lot was chosen as the reference.  The reference material is used to generate 
a standard curve for determining fermentation yields.  To establish the linear range of the 
reference, a full curve analysis containing both the upper asymptote and lower asymptote 
was performed.  For this purpose, C. perfringens type C toxoid bulk antigen lot 166263 
was selected as the reference material.  Full curve was achieved by starting the bulk 
material at a 1:2 dilution (diluted in 1% casein sodium in PBST) on the plate and serially 
diluted three-fold from columns 1 through 12 and ran in triplicate (Fig. 10).   
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Fig. 10: The linear portion of the reference material was established by full curve analysis 
using dilution 1:54 through 1:4,374 (boxed area).  Data is representative of mean OD 
(OD405 - OD490) for each dilution completed in triplicate.  The starting dilution of 
reference was 1:2 with three fold dilutions across the plate.  
  
 The reference was given an arbitrary stock concentration of 8,040 relative units 
per mL (RU/mL), which was based off the L+ value of the bulk antigen.  The first point 
of the linear region was a 1:54 dilution; this established the starting dilution of the 
reference for the in-process ELISA.  With a reference stock concentration of 8,040 
RU/mL, the starting dilution of the reference at 1:54 would be 148.89 RU/mL.  After a 
reference has been determined and assigned a stock concentration value, the next step 
was to establish a positive control to be used in the ELISA.  The positive control ensures 
that the reagents have not changed or degraded from assay to assay.   
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2.3.4.3 SELECTING A POSITIVE CONTROL 
 A positive control for an ELISA assay establishes the repeatability of the assay 
and stability of the reagents.  The positive control should be representative of the samples 
that will be analyzed in the assay and similar to the reference material, but from a 
different lot.  C. perfringens type C toxoid bulk antigen lot 183502 was selected as the 
positive control.  The positive control and the reference must be linear to each other as 
determined by calculating the slope ratio.  The slope ratio is calculated by dividing the 
slope of the positive control by the slope of the reference (Fig. 11).  Linearity is usually 
established with slope ratios within 0.8 – 1.25.    
 
 
Fig. 11: The linear equations for the reference and positive control contained similar 
slopes, yielding a slope ratio of 1.01.  Starting dilutions of reference (Ref.) and positive 
control (PC) was 1:54.     
 
 The slope for the positive control was -0.0982 and -0.0971 for the reference 
resulting in a slope ratio of 1.01, which was within the acceptable range.  After the use 
dilutions of the capture and indicator antibodies, and the reference and positive control 
42 
 
 
 
have been established, the next step is putting them into an appropriate assay format for 
assay optimization.  
 
2.3.4.4 IN-PROCESS ELISA FOR OPTIMIZATION   
 The following briefly describes the method used to optimize the in-process 
ELISA (as described in section 2.2.10).  The polyclonal capture antibody was dispensed 
onto a polystyrene 96-well plate and incubated overnight at 4°C.  The next day, the plate 
was blocked and incubated.  During incubation the reference, positive control and test 
articles were prepared for diluting onto a dilution plate.  The samples from the dilution 
plate were transferred to respective wells of the blocked plate and incubated.  The 
indicator antibody was added to the plate and then incubated.  Next, the peroxidase 
conjugate antibody was added to the plate and incubated.  ABTS peroxidase substrate 
was added to all wells on the plate.  The plate was read at 405 nm minus 490 nm 
targeting a ≥ 0.8 OD for the first dilution of the reference.  This targeted OD is used 
during the in-process ELISA optimization; during optimization steps an OD read range is 
established.   
 
2.3.5 IN-PROCESS ASSAY OPTIMIZATION STEPS 
2.3.5.1 MEAN, STANDARD DEVIATION AND COEFFICIENT OF VARIATION 
 To evaluate the in-process ELISA, three parameters are determined: the mean and 
standard deviation (STD) of replicate samples that are used to calculate the percent 
coefficient of variation (%CV).  The %CV is calculated by taking the standard deviation 
divided by the mean and multiplying by 100.  Low %CV indicates less variation between 
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replicates and higher precision of the assay.  A ≤15% CV would indicate the assay 
reagents are performing with acceptable consistency between replicates and in 
accordance with Veterinary Services Memoranda 800.112 (United States Department of 
Agriculture, 2017b).  Variability can arise from any step of the assay and these can be 
defined by five different methods for optimizing an assay as described below.     
 
2.3.5.2 INTRA-ASSAY PRECISION OR REPEATABILITY 
 One optimization parameter is to show the in-process ELISA intra-assay 
precision, which is a measure of how repeatable the assay is from plate to plate.  To 
assess precision and repeatability, one bulk lot was used in one sample position on the 
assay plate (i.e., T01, Fig. 1) on six different plates to achieve six replicates.  The RU/mL 
is calculated by individually applying a linear regression model to the reference, positive 
control and test samples.  If the slope ratio for the reference and positive control criteria 
are met, then the relative potency of the sample is calculated based on the difference in 
intercepts and common slopes of the reference and sample.  The linear regression model 
then calculates a RU/mL.  In order to estimate the repeatability, the %CV of the RU/mL 
was calculated to determine if the six replicates demonstrated a %CV ≤ 15%.     
Table 5: Intra-assay precision of the in-process ELISA.   
Antigen Lot Plate # RU/mL 
169196 
1 6230 
2 6307 
3 7023 
4 6163 
5 6447 
6 6365 
 Mean RU/mL 6423 
 STD 311 
%CV 5 
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 Intra-assay precision of the assay method was evaluated with bulk lot 169196 and 
the RU/mL results were calculated by measuring the bulk lot against the known reference 
(Table 5).  The %CV of the six replicates was 5%, meeting the criteria for intra-assay 
precision. 
 
2.3.5.3 WITHIN-PLATE PRECISION 
 The next step in assay optimization is to assess within-plate precision, which 
evaluates the variability between sample positions on a single plate using the same 
sample bulk.  A similar RU/mL result should be achieved regardless of which sample 
position (T01, T02 or T03) the test article is placed on the plate.  The RU/mL data from 
all three samples positions on two plates were analyzed in order to estimate and calculate 
the %CV for the within plate precision (Table 6). 
Table 6: Within-plate precision of the in-process ELISA.   
Antigen 
Lot Position 
Plate 1  Plate 2 
RU/mL 
183502 
T01 12252 12289 
T02 12210 11891 
T03 12699 12277 
Mean RU/mL 12387 12152 
STD 271 226 
%CV 2 2 
 
 Within-plate precision of the assay method was evaluated with bulk lot 183502 by 
testing all three sample positions on two separate plates.  Testing was completed on one 
day and the RU/mL was calculated by measuring the bulk lot 183592 against the known 
reference.  The %CV’s were less than 5% for the two plates, meeting the validation 
criteria for within-plate precision ≤ 15%. 
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2.3.5.4 INTERMEDIATE PRECISION 
 
 Another optimization step for the in-process assay is to show different personnel 
can achieve the same results with the same sample.  Intermediate precision is established 
by comparing assay results obtained from different technicians within the same 
laboratory.  The intermediate precision was assessed by evaluating one bulk lot at 100% 
and diluted to two different concentrations.  Two different analysts each performed two 
replicate plates.  Precision was evaluated by calculating the %CV for each preparation 
(Table 7). 
Table 7: Intermediate precision of the in-process ELISA.   
Antigen Lot Replicate Technician 
Sample 
T01 
(100%) 
T02  
(70%) 
T03  
(30%) 
RU/mL 
169196 
1 1 6697 4289 1888 
2 5863 3731 1692 
2 1 6420 4448 2035 
2 7074 4495 1811 
Mean RU/mL 6514 4241 1857 
STD 510 352 144 
%CV 8 8 8 
 
 Intermediate assay precision evaluated one bulk lot at three different 
concentrations which were 100%, 70% and 30%.  Intermediate CV’s for RU/mL was 
calculated by measuring the bulk lot 169196 against the known reference.  The %CV’s 
were 8%, meeting the validation criteria for intermediate precision of ≤ 15%. 
 
2.3.5.5 ACCURACY 
 After establishing intermediate precision, the next step for the in-process assay is 
to assess the accuracy of the assay.  Accuracy is the closeness of the assay value to the 
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predicted value based on analysis of the sample to the reference.  For example, a bulk lot 
can be measured relative to a standard curve to obtain a value for that bulk lot.  The same 
sample can then be diluted and the value should be known.  For instance, the accuracy of 
the assay was determined by comparing the measured RU/mL to the theoretical RU/mL 
of three bulk lot preparations.  The measured RU/mL of the non-diluted, 100%, bulk lot 
(T01) and its two diluted preparations, 70% and 30% (T02 and T03) were compared to 
their theoretical RU/mL.  The calculated difference (percent of theoretical) in RU/mL 
between measured and theoretical values were compared (Table 8).  The difference 
(percent of theoretical) in RU/mL between the measured and theoretical values for T02 
and T03 were calculated as follows; 
 Percent of theoretical RU/mL = 100 * (measured RU/mL ÷ theoretical RU/mL) 
Table 8: Comparison of measured RU/mL to theoretical RU/mL values demonstrating 
accuracy of the in-process ELISA. 
Antigen Lot 169196 173883 182291 
Rep Tech 
T01  T02 T03  T01  T02 T03  T01  T02 T03  
RU/mL 
1 1 6697 4289 1888 8426 5687 2490 7976 4862 2234 
2 5863 3731 1692 8707 6035 2514 9181 6122 2843 
2 1 6420 4448 2035 7792 5358 2256 7758 5576 2195 
2 7074 4495 1811 6649 5120 1905 9024 6151 2128 
Mean RU/mL 6514 4241 1857 7894 5550 2291 8485 5678 2350 
Theoretical 
RU/mL 
 
4560 1954 
 
5525 2368 
 
5939 2545 
% Theoretical 
 
93 95 
 
100 97 
 
96 92 
 
 The acceptance criterion for the accuracy of an assay has been internally 
established to fall within the range of 85 – 115 % theoretical.  The theoretical RU/mL is 
calculated by multiplying the non-diluted sample (T01) mean RU/mL result by 70% or 
30% for samples T02 and T03 respectively (Table 8).  Samples T02 and T03 for each of 
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the three bulk lots show the measured RU/mL relative to the calculated theoretical 
RU/mL and resulted in % theoretical values within the acceptable range. 
 
2.3.5.6 ROBUSTNESS   
 Determining robustness of an assay gives the operator a defined range of OD to 
yield confidence in the assay output.  Robustness of the assay with regard to plate reading 
range was evaluated by one analyst assaying one plate per day and repeating this over 
three days.  Each plate was read at a range of 0.6 – 1.1 OD for the reference lot 166263 
and the RU/mL data is analyzed by comparing %CV (Table 9). 
 The minimum and maximum read range was evaluated by one analyst.  The 
positive control (lot 183502) was used as the sample bulk measured for T01, T02 and 
T03.  On each of the three assay days, a single plate was read at an early (0.6) through 
late (1.1) OD.  The data shows that a reading range of the first reference dilution points, 
1:54 dilution (wells B2 and B7 in Figure 1), from 0.6 – 1.1 OD is an acceptable range for 
potency assay robustness, generating an overall average %CV of 3% across the three 
assay days. 
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Table 9: Variation between the minimum and maximum read range values.  
  
Day ODa  
PC T01 T02 T03 Mean 
RU/mL 
 Average 
%CV RU/mL 
1 
0.6 11608 11903 11311 11502 11572 
2 
0.7 11622 11795 11478 11498 11590 
0.8 11751 11877 11879 11577 11778 
0.9 11825 11890 11733 11902 11842 
1.0 12135 12223 12054 11648 11975 
1.1 12190 12594 12447 11931 12324 
2 
0.6 12720 12165 11448 13069 12227 
3 
0.7 12637 12477 11444 12714 12212 
0.8 12896 12252 12210 12699 12387 
0.9 13133 12580 11788 13278 12549 
1.0 13179 12830 12011 13429 12757 
1.1 13959 12872 13100 13121 13031 
3 
0.6 10689 9966 10107 10859 10311 
5 
0.7 10508 10111 10183 10461 10252 
0.8 10575 11135 10350 10838 10774 
0.9 10736 11324 10993 11050 11122 
1.0 11626 11487 11235 11497 11406 
1.1 11713 11599 11164 11221 11328 
aAverage OD reading of reference first dilution points in wells B2 and B7. 
 
 
2.3.5.7 ESTABLISHING POSITIVE CONTROL RANGE 
 After the other assay parameters had been optimized, the last step was to establish 
a positive control range.  The positive control range is another measurement used to 
ensure day to day and operator to operator consistency.  The assay is satisfactory when 
the positive control is within the range for each assay plate assessed.  Establishing the 
positive control range was achieved by three different technicians running six plates on 
three separate days.  The standard deviation of the mean was determined and the range 
was established by plus and minus two times the standard deviation of the mean.  The 
mean RU/mL from each of the three technicians and the positive control range was 
established to be 9,556 – 13,838 RU/mL (Table 10).   
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Table 10: Positive control range for the in-process ELISA was established using  
mean variation between three individual runs.   
Day/Tech Plate # PC lot 183502 (RU/mL) 
Day 1 Tech 1 1 11277 
2 11161 
3 11051 
4 11168 
5 10532 
6 11956 
Day 2 Tech 2 7 11599 
8 12297 
9 10087 
10 11749 
11 11908 
12 11631 
Day 3 Tech 3 13 11699 
14 11550 
15 12311 
16 11096 
17 15284 
18 12199 
Mean RU/mL 11698 
Standard Deviation (STD) 1070 
%CV 9 
Positive Control Range 
Ru/mLa 9,556 – 13,838 
aValues determined by ± two times the standard deviation of the mean. 
 
2.3.6 EVALUATION OF ELISA COMPARED TO L+ ASSAY  
 Eleven bulk antigens of C. perfringens type C toxoid with known L+ values were 
measured using the optimized in-process ELISA.  These results were plotted to determine 
the correlation between the two different assays (Fig. 12).  This analysis was done to 
determine if the in vitro ELISA could directly replace the mouse L+ assay as the in-
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process assay.  The cumulative R2 value was 0.4048 indicating low correlation of L+ 
values to measured RU/mL values.        
 
 
Fig. 12: L+ values compared to measured RU/mL values of eleven bulk antigen lots 
showed low correlation between L+ assay and in-process ELISA; R2 value of 0.4048 
(trend line).  
 
2.4 DISCUSSION 
 Clostridial species importance is due in part to the fact that they can be found in 
many environments including soil, water and mammals.  While they frequently exist as 
commensals, C. perfringens can be the cause of severe disease in both humans and 
animals.  Outbreaks of C. perfringens causing necrotic enteritis in neonates can have a 
great economic impact on livestock producers.  Effective vaccines have been developed 
to help prevent outbreaks, but they can be expensive due to the test methods involved in 
the production and release of the vaccines.  Currently, the beta toxoid form is a common 
immunogen used in C. perfringens type C vaccines.  To determine the potency of 
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production runs and facilitate blending of vaccines products, the potency test methods 
involve the use of lethal mouse assays.  An in vitro method for testing the beta toxoid of 
C. perfringens would reduce the expense of vaccine production by eliminating or 
reducing the use of laboratory animals.  The data presented in this thesis details the 
development of a robust and precise in-process ELISA method (below the industry 
standard of 15% CV) for detecting and quantifying beta toxoid in cultures of C. 
perfringens type C. 
 In this study, a monoclonal antibody specific to the beta toxoid from C. 
perfringens type C was generated and selected for developing an in vitro in-process 
ELISA assessing beta toxoid yield.  This monoclonal antibody had high specificity to the 
beta toxin via western blot, produced a high ELISA signal to the beta toxoid and strong 
neutralizing activity with no cross reactivity to C. perfringens type A alpha toxoid.  This 
monoclonal antibody, and a selected polyclonal antibody, allowed for the development of 
an in-process ELISA that is specific to the beta toxoid.   
 The development of in vitro Clostridium toxoid assays has produced a diverse 
collection of protocols with varying utility.  Redhead, K., et al. described a C. septicum 
in-process assay using Vero cells, which are sensitive to the toxin from C. septicum, and 
showed a correlation between their cell-based assay and mouse L+ test assay results.  
They concluded the mouse L+ test could be replaced by their cell-based assay (Redhead 
et al., 2011).  While the cell-based assay was more accurate than the mouse L+ test and 
eliminated the use of mice, this method measures toxin but cannot quantify toxoid in 
production fermentation batches.  In addition to cell line-based assays, ELISA methods 
(i.e., sandwich, blocking, and competitive assays) have been used to develop serological 
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assays for measuring the presence of anti-C. perfringens beta toxin in rabbits, pigs, cattle, 
sheep and horse serum.  ELISA methods have the potential to reduce the use of mice for 
assessing the presence of serum antibodies in the final potency test, but does not 
eliminate animal usage altogether (Krt, 1999).  Another ELISA method tried to replace 
the mouse neutralization test for estimating levels of beta toxin antitoxin in the sera of 
immunized rabbits for final potency testing.  This in vitro method uses an ELISA where a 
monoclonal antibody to beta toxin is coated on the plate to capture C. perfringens beta 
toxin, which then binds beta antitoxin in rabbit sera (Ebert et al., 1999).  While this 
method had a good correlation between in vivo and in vitro for testing sera potencies, 
rabbits are still vaccinated first in order to obtain final potency results.  To date, the 
available assays were not designed for quantifying antigen for vaccine input.  The 
sandwich ELISA described in this thesis is an alternative to the current L+ test that will 
potentially reduce the use of experimental animals.  An ELISA would be a high through 
put advantage able to test greater number of samples in a shorter period of time, more 
economical and have better consistency of batch to batch vaccine assembly in 
comparison to assembling vaccines based on in vivo testing.  This ELISA would also 
have the potential to replace the current potency testing of C. perfringens type C vaccines 
as described in 113.111 of the USDA 9CFR and in monograph 363 of the EP.   
 The research described here has shown the development of an optimized ELISA 
method for detecting and quantifying C. perfringens type C beta toxoid.  However, the in 
vivo L+ values were shown not to correlate with the ELISA RU/mL values.  Figure 12 
illustrated there was low correlation between the L+ values and the average measured 
RU/mL values.  Values generated by the L+ assay are not directly indicative of the 
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quantity of beta toxin present in the C. perfringens type C material, which could be why 
variability is seen in animal testing.  The L+ is measuring the antigenicity of toxin verses 
the toxoid being quantified with a specific antibody in the in-process ELISA.   
 In order to replace the L+ test with the developed ELISA, additional experiments 
would need to be completed.  Using the developed ELISA, one approach would be to 
perform the in-process ELISA method on formulated vaccines.  If the in-process ELISA 
could also detect beta toxoid in final vaccine, then this would aide in quantitatively 
determining the protective dose in current vaccines.  Another approach would be to 
obtain toxoid antigen with known L+ value and measure the toxoid material in the in-
process assay to determine the respective RU/mL value of the bulk.  Vaccines could be 
prepared with toxoid antigen at different RU/mL levels for vaccinating mice and the mice 
would be challenged with a known amount of beta toxin that is lethal in mice.  By 
repeating this with multiple antigen bulks of type C toxoid, one could define the potential 
protective dose in mice.  After mouse challenge studies had been completed, large animal 
studies, species specific, would need to be conducted showing the protective minimum 
immunizing dose (MID).  This is now possible due to the generation of reagents which 
are the monoclonal and polyclonal antibodies to beta toxoid material as well as the 
method for use of those reagents.       
 In my research, I assessed and selected a polyclonal and a monoclonal antibody 
and optimized the concentrations used to detect the C. perfringens type C toxoid.  These 
antibodies had specificity to beta toxin and toxoid and exhibited neutralizing activity; 
hence, can to be used as the capture and indicator for developing an in-process ELISA.  
The USDA requires the reagents in these types of in vitro methods correlate to protection 
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either by specificity to protective epitopes or by the ability to neutralize antigens that 
cause disease.  Through a combination of western blots, neutralization assay and 
ELISA’s, I identified which antibodies would be appropriate for the assay.  This 
optimized in-process ELISA could potentially replace the mouse L+ test which would 
reduce the use of animals to measure the type C toxoid material and potentially improve 
C. perfringens type C vaccine production through batch to batch consistency, decreased 
testing time and could improve cost of the product.   
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